Advanced Medical Solutions GroupLSE:AMS +16.04%89 ROE % is 2.91% as of Dec. 2025, which is 67% below its 10-year median of 8.76. GuruFocus rates LSE:AMS with a GF Score™ of 89/100 and a GF Value™ of £3.69 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks better than 55.07% on this metric.
LSE:AMS'
s ROE % Range Over the Past 10 Years
Min: 2.93 Med: 8.76 Max: 14.49
Current: 3.95
During the past 13 years, Advanced Medical Solutions Group's highest ROE % was 14.49%. The lowest was 2.93%. And the median was 8.76%.
LSE:AMS's ROE % is ranked better than 55.07% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs LSE:AMS: 3.95
Advanced Medical Solutions Group (LSE:AMS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Advanced Medical Solutions Group ROE % Related Terms
Advanced Medical Solutions Group ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's ROE % distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Advanced Medical Solutions Group (LSE:AMS) has a ROE % of 2.91% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Advanced Medical Solutions Group and its competitors. This is 67% below median its historical median of 8.76. Over the past decade, Advanced Medical Solutions Group's ROE % has ranged from 2.93 to 14.49. According to the industry distribution chart, Advanced Medical Solutions Group ranks #359 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 44.9%.
Is Advanced Medical Solutions Group's ROE % too high?
Advanced Medical Solutions Group's current ROE % of 2.91% is 67% below median its 10-year median of 8.76. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 14.49. The Medical Devices & Instruments industry median ROE % is 2.42. Advanced Medical Solutions Group's value of 2.91% is 20.2% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #359 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #359 out of 799 companies for ROE %. This puts Advanced Medical Solutions Group in the upper half of its industry. The industry median ROE % is 2.42. Advanced Medical Solutions Group's value of 2.91% is 20.2% above this benchmark. Historically, Advanced Medical Solutions Group's own ROE % has ranged from 2.93 to 14.49 over the past decade. While the company's 10-year median is 8.76 vs. the industry median of 2.42, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current ROE % of 2.91% is 20.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current ROE % is 2.91%, which is 67% below median its own 10-year median of 8.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (LSE:AMS) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.69, compared to a current price of £2.79 — trading 24.5% below its estimated fair value. The current ROE % is 2.91%, which is 67% below median its 10-year median of 8.76 and 20.2% above the Medical Devices & Instruments industry median of 2.42. Advanced Medical Solutions Group's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Advanced Medical Solutions Group (LSE:AMS), the current ROE % is 2.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (LSE:AMS) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.79 is trading 24.5% below its estimated GF Value™ of £3.69.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for LSE:AMS:
ROE %: 2.91% (67% below median its 10-year median of 8.76)
GF Value™: £3.69 vs. price of £2.79 (24.5% below fair value)
Industry Position: 20.2% above the Medical Devices & Instruments median (#359 of 799)
No single metric tells the full story. See the LSE:AMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
89GF Score
Get the complete analysis for LSE:AMS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AMS has been successfully added to your 
